FNY Investment Advisers LLC Increases Stake in Ginkgo Bioworks Holdings, Inc. $DNA

FNY Investment Advisers LLC lifted its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 12.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 149,971 shares of the company’s stock after acquiring an additional 16,380 shares during the period. FNY Investment Advisers LLC’s holdings in Ginkgo Bioworks were worth $1,687,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. US Bancorp DE lifted its holdings in shares of Ginkgo Bioworks by 43.5% during the 1st quarter. US Bancorp DE now owns 6,302 shares of the company’s stock worth $36,000 after acquiring an additional 1,911 shares during the period. CWM LLC lifted its holdings in shares of Ginkgo Bioworks by 667.6% during the 1st quarter. CWM LLC now owns 12,274 shares of the company’s stock worth $70,000 after acquiring an additional 10,675 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Ginkgo Bioworks during the 2nd quarter worth about $148,000. Fox Run Management L.L.C. purchased a new position in shares of Ginkgo Bioworks during the 1st quarter worth about $76,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Ginkgo Bioworks during the 1st quarter worth about $120,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Ginkgo Bioworks news, insider Steven P. Coen sold 5,609 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $15.00, for a total transaction of $84,135.00. Following the sale, the insider directly owned 5,503 shares in the company, valued at $82,545. The trade was a 50.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 9.72% of the stock is currently owned by company insiders.

Ginkgo Bioworks Price Performance

Ginkgo Bioworks stock opened at $13.14 on Wednesday. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $17.58. The company has a market capitalization of $777.83 million, a price-to-earnings ratio of -2.24 and a beta of 1.54. The firm’s fifty day moving average price is $12.68 and its 200 day moving average price is $10.44.

Ginkgo Bioworks (NYSE:DNA) last announced its earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.44) by $0.34. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%.The company had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. Analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Cowen restated a “buy” rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, October 8th. BTIG Research raised their price target on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the company a “sell” rating in a report on Monday, August 25th. Finally, Wall Street Zen upgraded shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday, August 30th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $9.00.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.